期刊
JOURNAL OF DERMATOLOGICAL TREATMENT
卷 31, 期 4, 页码 333-341出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2019.1603361
关键词
Psoriasis; Corrona Psoriasis Registry; secukinumab; effectiveness
类别
资金
- AbbVie
- Amgen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Crescendo
- Eli Lilly and Company
- Genentech
- Gilead
- GlaxoSmithKline
- Janssen
- Merck
- Momenta Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Valeant
- Eli Lilly
- Janssen/Johnson Johnson
- Kadmon
- MedImmune/AstraZeneca
- Vidac
Objective: To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry. Methods: Eligible patients aged >= 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit (window: 5-9 months) as of December 31 2017, were included in the analysis. Measures of disease severity and PROs were assessed in patients who maintained secukinumab treatment at the 6-month follow-up visit. Results: Of the 144 patients who initiated secukinumab at enrollment and had a 6-month follow-up visit, 118 (81.9%) maintained secukinumab treatment at 6 months and demonstrated significant improvements in affected body surface area (BSA) and 5-point Investigator's Global Assessment (IGA) score (all p < .01). The majority of patients were biologic experienced (89.8%). In addition, patients reported significant improvements in quality of life, as well as in pain, itch, fatigue, work productivity, and daily activities (all p < .01). Conclusions: Secukinumab significantly improved disease severity and PROs after 6 months of follow-up in this real-world study, which is consistent with other current real-world studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据